Company
Scilex Holding Co (SCLX)
Standardized SEC financial data for Scilex Holding Co — income statement, balance sheet, cash flow and 40+ ratios, as a clean JSON API. CIK 0001820190 · NASDAQ · Biological Products, (No Diagnostic Substances).
Operating margin
-1000.0%
Net margin
-1000.0%
Revenue growth (YoY)
-46.5%
Return on equity
176.7%
Free cash flow
$3.7M
Debt / equity
0.00×
Current ratio
0.08×
EPS (diluted)
$-36.48
Ratios for fiscal year 2025, standardized from SEC filings.
Income statement
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $23.6M | $31.3M | $38.0M | $46.7M | $56.6M | $30.3M |
| Cost of revenue |
Balance sheet
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $4.8M | $4.3M | $2.2M | $4.7M | $3.3M | $5.0M |
| Accounts receivable |
Cash flow
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$31.5M | -$28.7M | $21.3M | -$20.7M | $19.3M | $3.8M |
| Capital expenditures |
Get SCLX data via API
# JSON
curl https://sec-financial-api-production.up.railway.app/v1/company/SCLX/financials \
-H "X-API-Key: YOUR_KEY"
# CSV export (income / balance / cash-flow)
curl "https://sec-financial-api-production.up.railway.app/v1/company/SCLX/income-statement?format=csv" \
-H "X-API-Key: YOUR_KEY"